The Center for Biosimilars

The move will create Europe's largest generics company.

In a statement, Fresenius Kabi officials said the company is rapidly expanding its portfolio in autoimmune and oncology conditions.

Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention of the prescribing clinician.

The deal follows a string of trials and settlements totaling $550 million in separate cases around the country.

Teva’s launch makes it the first competitor to Revlimid in the United States, but perhaps not the last.

Tuznue, which references Roche’s Herceptin, is currently under review for marketing authorization by the EU European Medicines Agency, Canada, and South Korea.

The IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high-quality, safe, and effective medicines while reducing costs in pharmaceutical care.

Xolair, the only currently approved product containing omalizumab, was first approved in 2003. AVT23 is an investigational compound and has not received regulatory approval in any country. Current sales of Xolair are estimated at $3.3 billion.

A September 29, 2020, symposium with Sonia T. Oskouei, PharmD, BCMAS, DPLA, of Cardinal Health will explore how to incorporate biosimilars into the treatment of inflammatory conditions.

Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.

Ruth O’Regan, of the University of Wisconsin Carbone Cancer Center, discusses improving the patient discussion on biosimilars, in an interview.

With 1 biosimilar launch and expanded indications for another biosimilar so far this year, Teva Pharmaceutical Industries reported higher biosimilar revenues in the first quarter of 2020.

Bausch + Lomb has secured the rights to commercialize a ranibizumab biosimilar in the United States and Canada.

Amgen saw biosimilar competition eat a larger share of its innovator drug revenue but also earned some biosimilar pocket money of its own.

A smattering of biosimilar launches around the globe and positive results for biosimilar earnings across companies suggested a positive trend in April, despite the ongoing pandemic.

The Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the marketing authorization of Insulin aspart Sanofi.

The reasons for biosimilar brand preference in a recent rituximab study were unclear, but investigators said it is clear that savings were a likely factor.

With a growing portfolio of biosimilars, Novartis saw a 31% increase in biopharmaceutical sales for the first quarter of 2020, despite the pandemic.

One only needs to look at Europe to see the future, says a pharmacy expert, who sees the US payer landscape moving to greater biosimilar adoption in 2020.

Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, discusses the sticker shock of rising specialty drug costs and how biosimilars are going to be incorporated into efforts to push back against this medical inflation.

Ha Kung Wong, JD, a patent law attorney with Venable of New York, New York, discusses recent regulatory actions to promote biosimilars.

Biosimilar pricing is not as simple as a manufacturer's stated discount to the reference product cost, according to Adam Brufsky, MD, PhD, FACP, of the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.

A panel of experts discusses the rising class of biological agents and why clinical pharmacists need to deepen their knowledge.

A bill designed to provide assistance to patients who cannot afford their insulin was signed into law by Minnesota Governor Tim Walz.

A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.

After noting the stories of individuals with diabetes dying due to their inability to afford insulin, the Minnesota House has passed an emergency insulin bill that is expected to move rapidly through the Senate to the governor’s desk.

With the launch of Mylan and Biocon’s pegfilgrastim biosimilar, Australia adds another biosimilar to its portfolio of biosimilars in circulation.

The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use.

Oncologist/hematologist Lee S. Schwartzberg, MD, FACP, describes some important considerations for using biosimilars in clinical practice.

NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.